170 related articles for article (PubMed ID: 20395744)
1. Further development and evaluation of a breast/ovarian cancer genetics referral screening tool.
Bellcross C
Genet Med; 2010 Apr; 12(4):240. PubMed ID: 20395744
[No Abstract] [Full Text] [Related]
2. Impact of Implementing B-RST
Wernke K; Bellcross C; Gabram S; Ali N; Stanislaw C
Clin Breast Cancer; 2019 Aug; 19(4):e547-e555. PubMed ID: 31005475
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population.
Bellcross CA; Lemke AA; Pape LS; Tess AL; Meisner LT
Genet Med; 2009 Nov; 11(11):783-9. PubMed ID: 19752737
[TBL] [Abstract][Full Text] [Related]
4. BRCA screening.
Med Lett Drugs Ther; 2007 Nov; 49(1274):93-4. PubMed ID: 18007543
[No Abstract] [Full Text] [Related]
5. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
[TBL] [Abstract][Full Text] [Related]
6. Genetic/familial high-risk assessment: breast and ovarian.
Daly MB; Axilbund JE; Buys S; Crawford B; Farrell CD; Friedman S; Garber JE; Goorha S; Gruber SB; Hampel H; Kaklamani V; Kohlmann W; Kurian A; Litton J; Marcom PK; Nussbaum R; Offit K; Pal T; Pasche B; Pilarski R; Reiser G; Shannon KM; Smith JR; Swisher E; Weitzel JN;
J Natl Compr Canc Netw; 2010 May; 8(5):562-94. PubMed ID: 20495085
[No Abstract] [Full Text] [Related]
7. Validation of Version 3.0 of the Breast Cancer Genetics Referral Screening Tool (B-RST™).
Bellcross C; Hermstad A; Tallo C; Stanislaw C
Genet Med; 2019 Jan; 21(1):181-184. PubMed ID: 29740170
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of BRCA1/2 mutation testing in 466 breast/ovarian cancer families.
Evans DG; Bulman M; Young K; Gokhale D; Lalloo F
J Med Genet; 2003 Sep; 40(9):e107. PubMed ID: 12960223
[No Abstract] [Full Text] [Related]
9. Variability in Cancer Risk with BRCA Mutations.
Cancer Discov; 2015 Jul; 5(7):OF16. PubMed ID: 25952264
[No Abstract] [Full Text] [Related]
10. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
Shulman LP
Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261
[TBL] [Abstract][Full Text] [Related]
11. Uptake of genetic counseling and multi-gene panel testing among women in the Intermountain West with previous negative BRCA1 and BRCA2 results contacted for updated testing.
Mooney R; Espinel W; Elrick A; Kehoe K; Kohlmann W; Kaphingst KA
J Genet Couns; 2022 Apr; 31(2):470-478. PubMed ID: 34570943
[TBL] [Abstract][Full Text] [Related]
12. Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations.
Wood ME; Garber JE; Isaacs C; Masood S; Bedrosian I; Tung N; Chun J; Schnabel FR; Arun BK;
Breast J; 2019 Jul; 25(4):575-577. PubMed ID: 31280501
[No Abstract] [Full Text] [Related]
13. Novel and recurrent BRCA1/BRCA2 mutations in early onset and familial breast and ovarian cancer detected in the Program of Genetic Counseling in Cancer of Valencian Community (eastern Spain). Relationship of family phenotypes with mutation prevalence.
de Juan Jiménez I; García Casado Z; Palanca Suela S; Esteban Cardeñosa E; López Guerrero JA; Segura Huerta Á; Chirivella González I; Sánchez Heras AB; Juan Fita MJ; Tena García I; Guillen Ponce C; Martínez de Dueñas E; Romero Noguera I; Salas Trejo D; Goicoechea Sáez M; Bolufer Gilabert P
Fam Cancer; 2013 Dec; 12(4):767-77. PubMed ID: 23479189
[TBL] [Abstract][Full Text] [Related]
14. Finding all BRCA pathogenic mutation carriers: best practice models.
Hoogerbrugge N; Jongmans MC
Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S19-26. PubMed ID: 27514840
[TBL] [Abstract][Full Text] [Related]
15. The yield of full BRCA1/2 genotyping in Israeli Arab high-risk breast/ovarian cancer patients.
Bernstein-Molho R; Barnes-Kedar I; Ludman MD; Reznik G; Feldman HB; Samra NN; Eilat A; Peretz T; Peretz LP; Shapira T; Magal N; Kalis ML; Yerushalmi R; Vinkler C; Liberman S; Basel-Salmon L; Shohat M; Levy-Lahad E; Friedman E; Bazak L; Goldberg Y
Breast Cancer Res Treat; 2019 Nov; 178(1):231-237. PubMed ID: 31368036
[TBL] [Abstract][Full Text] [Related]
16. Counseling the at risk patient in the BRCA1 and BRCA2 Era.
Barnes-Kedar IM; Plon SE
Obstet Gynecol Clin North Am; 2002 Jun; 29(2):341-66, vii. PubMed ID: 12108833
[TBL] [Abstract][Full Text] [Related]
17. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
[TBL] [Abstract][Full Text] [Related]
18. [Genetic testing in patients at risk for carcinoma of the breast].
Kiechle M
Dtsch Med Wochenschr; 2006 Oct; 131(43):2420-2. PubMed ID: 17054060
[No Abstract] [Full Text] [Related]
19. Assessment of blind predictions of the clinical significance of BRCA1 and BRCA2 variants.
Cline MS; Babbi G; Bonache S; Cao Y; Casadio R; de la Cruz X; Díez O; Gutiérrez-Enríquez S; Katsonis P; Lai C; Lichtarge O; Martelli PL; Mishne G; Moles-Fernández A; Montalban G; Mooney SD; O'Conner R; Ootes L; Özkan S; Padilla N; Pagel KA; Pejaver V; Radivojac P; Riera C; Savojardo C; Shen Y; Sun Y; Topper S; Parsons MT; Spurdle AB; Goldgar DE;
Hum Mutat; 2019 Sep; 40(9):1546-1556. PubMed ID: 31294896
[TBL] [Abstract][Full Text] [Related]
20. Precision medicine meets public health: population screening for BRCA1 and BRCA2.
Levy-Lahad E; Lahad A; King MC
J Natl Cancer Inst; 2015 Jan; 107(1):420. PubMed ID: 25550384
[No Abstract] [Full Text] [Related]
[Next] [New Search]
